Guide AI - Stock Ticker - Der Markt Heutede

— SIX KEY TAKEAWAYS —

Data Moat: Exclusive access, through its partnership with vRad, to more than 1 billion medical images from 2,100+ hospitals — one of the largest training datasets in peripheral vascular AI.
FDA Clearance in Hand: VAOT received 510(k) clearance in June 2026 and is commercially available now — not a someday roadmap item.
First-Mover Advantage: Viz.ai, Aidoc, Cleerly, and HeartFlow all build AI for other vascular territories. None of them cover peripheral arterial disease. GuideAI stands alone.
A Real Hospital Pipeline: 200+ global hospital letters of intent, including a signed LOI from Advocate Health — a 69-hospital system serving 6 million patients a year.
A Business Model That Compounds: Recurring annual SaaS contracts, priced per site, reaching up to $3 million per year at full deployment as new disease modules are added
A Second Product Already Coming: CarotidAssist™ is expected to receive FDA 510(k) clearance as early as Q1 2027 — a second disease area on the same infrastructure.